Sponsored Content

Fucoidan research surpasses 5000 studies

11 Oct 2026

Global research interest in the marine extract fucoidan continues to surge, with the number of published, peer-reviewed papers recently surpassing 5000.

Australian biotechnology company Marinova confirms that scientific interest in fucoidan has risen rapidly in the past five years. ”In 2025 alone, more than 550 papers were published,” said the company’s Research Director Dr Barbara Wimmer. “The research momentum within the global scientific community is on track to exceed this figure by approximately 10% in 2026.”

Fucoidans are complex polysaccharides that have been shown to impart a wide range of beneficial bioactivities. “They are utilised in innovative nutraceutical, medical device and skincare applications for their gut health, immune support and healthy ageing benefits,” explained Dr Wimmer. “High purity, certified organic fucoidans are multifunctional ingredients that have been extensively studied. Sustainably sourced and clinically validated, they tick all the boxes for brands looking to capture consumer demand for natural and efficacious products.”

• Fucoidans are complex polysaccharides produced naturally by brown seaweeds 
• More than 5000 published papers attest to their various bioactivities 
• Maritech® organic fucoidans are the world’s only high purity, certified organic fucoidan extracts with global regulatory acceptance, including FDA-notified GRAS and EU Novel Foods authorisation
• Supplied as a dry powder, water soluble, easy to formulate

“Marinova remains a leading contributor to global fucoidan research, recently publishing the world’s first clinical trial investigating high purity fucoidan and prostate health,” said Dr Wimmer. “Based on the significant relief of lower urinary tract symptoms and improved prostate-related quality-of-life, we expect fucoidan to have a bright future in the field of men’s urinary health.”

Research figures from scopus.com

Read More